Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 924 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Psoriasis Clear all
Completed No phase listed Observational Accepts healthy volunteers

Characterization of Lipoprotein Composition and Function in Pediatric Psoriasis Before and After Treatment

NCT03791216
View directory record Official record
Conditions
Psoriasis
Interventions
Fasting blood draw for lipid assessments
Other
Lead sponsor
Northwestern University
Other
Eligibility
6 Years to 17 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 22, 2026, 2:00 AM EDT
Recruiting No phase listed Observational

Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors

NCT04751396
View directory record Official record
Conditions
Ankylosing Spondylitis, Autoimmune Disease, Crohn Disease, Enteropathic Arthritis, Enteropathic Spondylitis, Inflammatory Bowel Disease, Melanoma, Psoriasis, Psoriatic Arthritis, Reactive Arthritis, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Ulcerative Colitis
Interventions
Best Practice, Educational Intervention, Interview, Questionnaire Administration, Survey Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 22, 2026, 2:00 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis

NCT02201524
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
PF-04965842, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
35
States / cities
Birmingham, Alabama • Rogers, Arkansas • Encinitas, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2016 · Synced Oct 22, 2026, 2:00 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Prurisol Administered Orally for Active Mild to Moderate Chronic Plaque Psoriasis

NCT02494479
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Prurisol, Placebo
Drug
Lead sponsor
Cellceutix Corporation
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
9
States / cities
Huntsville, Alabama • Encino, California • Coral Gables, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2017 · Synced Oct 22, 2026, 2:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis

NCT03210961
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
PF-06826647 tablet, PF-06826647 oral suspension, Placebo oral solution/suspension, Placebo tablet
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Oct 22, 2026, 2:00 AM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)

NCT03162796
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
9
States / cities
Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 22, 2026, 2:00 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Trial of CF101 to Treat Patients With Psoriasis

NCT01265667
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
CF101, Placebo
Drug
Lead sponsor
Can-Fite BioPharma
Industry
Eligibility
18 Years to 80 Years
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Oct 22, 2026, 2:00 AM EDT
Recruiting Phase 4 Interventional

Taltz in Combination With Enstilar for Psoriasis

NCT04372277
View directory record Official record
Conditions
Psoriasis
Interventions
Enstilar
Drug
Lead sponsor
Psoriasis Treatment Center of Central New Jersey
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
East Windsor, New Jersey
Source: ClinicalTrials.gov public record
Updated May 4, 2020 · Synced Oct 22, 2026, 2:00 AM EDT
Terminated Not applicable Interventional Results available

Excimer Laser Phototherapy Outcomes in the Treatment of Psoriasis

NCT02294981
View directory record Official record
Conditions
Psoriasis
Interventions
Excimer laser phototherapy
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2020 · Synced Oct 22, 2026, 2:00 AM EDT
Completed Phase 2 Interventional Results available

A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis

NCT02564042
View directory record Official record
Conditions
Psoriasis
Interventions
GSK2894512 1% Cream, GSK2894512 0.5% Cream, Vehicle cream
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
18
States / cities
San Diego, California • North Logan, Connecticut • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 22, 2026, 2:00 AM EDT
Completed Phase 4 Interventional Results available

Efficacy/Safety/Subject Satisfaction/Duration of Response of Clobetasol Propionate Spray vs Ointment in Plaque Psoriasis

NCT00733954
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
clobetasol propionate spray, clobetasol propionate ointment
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 80 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
6
States / cities
Fremont, California • Vallejo, California • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Oct 22, 2026, 2:00 AM EDT
Completed Not applicable Interventional

An Exploratory Study to Evaluate a Digital Intervention to Disrupt Scratching in Atopic Dermatitis and Psoriasis

NCT06275659
View directory record Official record
Conditions
Psoriasis, Atopic Dermatitis
Interventions
CT-100-004-A, CT-100-004-B
Device
Lead sponsor
Click Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 22, 2026, 2:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of BMS-986165 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients

NCT03262727
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Arthritic Psoriasis, Psoriasis, Inflammatory Bowel Diseases
Interventions
BMS-986165, Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Oct 22, 2026, 2:00 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Brain Changes in Psoriasis After Secukinumab Treatment

NCT04717466
View directory record Official record
Conditions
Psoriasis, Healthy
Interventions
Secukinumab
Biological
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 22, 2026, 2:00 AM EDT
Completed Phase 2 Interventional

Evaluation of Clinical Outcomes in an Online Teledermatology Model for the Management of Psoriasis

NCT00971477
View directory record Official record
Conditions
Psoriasis
Interventions
Online Teledermatology Care, Conventional in Office Care
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 13, 2010 · Synced Oct 22, 2026, 2:00 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

PPD™ CorEvitas™ Psoriasis (PSO) Early Treatment Response Non-Interventional Study

NCT07648602
View directory record Official record
Conditions
Psoriasis
Interventions
Observational (Non-Interventional) Registry
Other
Lead sponsor
CorEvitas
Network
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2036
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 22, 2026, 2:00 AM EDT
Active, not recruiting Phase 2 Interventional

Effisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous Study

NCT03886246
View directory record Official record
Conditions
Generalized Pustular Psoriasis
Interventions
Spesolimab
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
12 Years to 75 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
2
States / cities
Auburn Hills, Michigan • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 22, 2026, 2:00 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Rheumatology Patient Registry and Biorepository

NCT04402086
View directory record Official record
Conditions
Rheumatic Diseases, Adult Onset Still Disease, Ankylosing Spondylitis, Psoriatic Arthritis, Reactive Arthritis, Antiphospholipid Syndrome, Systemic Lupus Erythematosus, Behcet Disease, Dermatomyositis, Polymyositis, Giant Cell Arteritis, Lyme Disease, Mixed Connective Tissue Disease, Polymyalgia Rheumatica, Rheumatoid Arthritis, Sarcoidosis, Systemic Sclerosis, Scleroderma, Sjogren's Syndrome, Undifferentiated Connective Tissue Diseases
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
18 Years to 99 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 22, 2026, 2:00 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )

NCT03047395
View directory record Official record
Conditions
Psoriasis
Interventions
risankizumab
Biological
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
2,170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
79
States / cities
Birmingham, Alabama • Rogers, Arkansas • Bakersfield, California + 65 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 22, 2026, 2:00 AM EDT
Completed Phase 4 Interventional Results available

Study of the Efficacy of Cloderm® Cream in the Treatment of Moderate Plaque Psoriasis

NCT01714544
View directory record Official record
Conditions
Psoriasis
Interventions
Cloderm Cream
Drug
Lead sponsor
Promius Pharma, LLC
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
5
States / cities
Cincinnati, Ohio • Portland, Oregon • Austin, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced Oct 22, 2026, 2:00 AM EDT
Recruiting Phase 1 Interventional

Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis

NCT06982352
View directory record Official record
Conditions
Atopic Dermatitis (AD), Psoriasis (PsO)
Interventions
LPX-TI641, Placebo
Drug
Lead sponsor
LAPIX Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Fargo, North Dakota • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 22, 2026, 2:00 AM EDT
Completed Phase 2 Interventional

Alefacept Mechanism of Action in Psoriasis

NCT00150982
View directory record Official record
Conditions
Psoriasis
Interventions
Mechanism of action of alefacept
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 7, 2008 · Synced Oct 22, 2026, 2:00 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of IDP-118 in Participants With Plaque Psoriasis

NCT02462122
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
IDP-118 Lotion, IDP-118 Vehicle Lotion
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
16
States / cities
Fremont, California • Boynton Beach, Florida • North Miami Beach, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 22, 2026, 2:00 AM EDT
Terminated No phase listed Observational

AMEVIVE® Pregnancy Registry

NCT00342862
View directory record Official record
Conditions
Pregnancy
Interventions
Amevive exposure
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 11, 2013 · Synced Oct 22, 2026, 2:00 AM EDT